natural killer cell therapy

Phase 2Cell therapy

natural killer cell therapy is one of 171 biologic programs targeting Skin Basal Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

170

Competitors

Pipeline

Status by Indication[3][1]

Indication

Skin Basal Cell CarcinomaActive, not recruiting

Blood DiseaseActive, not recruiting

Chronic Myelogenous LeukemiaActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

MelanomaActive, not recruiting

Multiple MyelomaActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Adult T-Cell Leukemia/lymphomaActive, not recruiting

Skin Squamous Cell CarcinomaActive, not recruiting

Skin Basal Cell CarcinomaPhase 1

Active, not recruiting

Blood DiseasePhase 2

Active, not recruiting

Chronic Myelogenous LeukemiaPhase 1/Phase 2

Active, not recruiting

Myelodysplastic SyndromePhase 2

Active, not recruiting

MelanomaPhase 1/Phase 2

Active, not recruiting

Multiple MyelomaPhase 2

Active, not recruiting

Acute Myeloid LeukemiaPhase 1

Active, not recruiting

Adult T-Cell Leukemia/lymphomaPhase 1

Active, not recruiting

Skin Squamous Cell CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Ninlaro

Takeda

Preclinical

18 2

natural killer cell therapy

MM.D. Anderson Cancer Center

Phase 2

1 3

Prolia

Amgen

Preclinical

5 4

Eliquis

Bristol-Myers Squibb

Preclinical

3 5

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 6

Adriamycin

GGynecologic Oncology Group

Preclinical

9 7

Nolvadex

AstraZeneca

Preclinical

1 8

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 9

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 10

Oblimersen Sodium

NNational Cancer Institute (NCI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Skin Basal Cell Carcinoma

NCT07144384

Q1 2027

Phase 1Recruiting

Adult T-Cell Leukemia/lymphoma

NCT04848064

Clinical

Trials by Indication[1]

Natural Killer Cell2 trials

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00354172·16 enrolled

Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02271711·12 enrolled

Blood Disease1 trial

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT00450983·1 enrolled

Melanoma1 trial

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

Recruiting·KKari Kendra·Phase 1/2·NCT05588453·30 enrolled

Multiple Myeloma1 trial

Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01729091·72 enrolled

Transplantation1 trial

NK Cells in Cord Blood Transplantation

Unknown status·MM.D. Anderson Cancer Center·Phase 1·NCT01619761·13 enrolled

7 more indications

Relapsed or Refractory Hematologic Malignancies1 trial

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT02259348·12 enrolled

Bone Marrow Transplant1 trial

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00789776·41 enrolled

Myelodysplastic Syndrome1 trial

Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00526292·12 enrolled

Chronic Myelogenous Leukemia1 trial

Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01904136·54 enrolled

Adult T-Cell Leukemia/lymphoma1 trial

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

Recruiting·JJohn Reneau·Phase 1·NCT04848064·12 enrolled

Acute Myeloid Leukemia1 trial

Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·SSumithira Vasu·Phase 1·NCT02316964·8 enrolled

Skin Basal Cell Carcinoma1 trial

A Pilot Study Testing Intralesional Injection of Ex-Vivo Expanded Allogenic University Donor (UD) NK and TGFBi NK Cells in Patients With Cutaneous Keratinocyte Carcinomas

Active, not recruiting·KKirsten Johnson·Phase 1·NCT07144384·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for natural killer cell therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — natural killer cell therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for natural killer cell therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: MM.D. Anderson Cancer Center

natural killer cell therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Natural Killer Cell2 trials

Blood Disease1 trial

Melanoma1 trial

Multiple Myeloma1 trial

Transplantation1 trial

Relapsed or Refractory Hematologic Malignancies1 trial

Bone Marrow Transplant1 trial

Myelodysplastic Syndrome1 trial

Chronic Myelogenous Leukemia1 trial

Adult T-Cell Leukemia/lymphoma1 trial

Acute Myeloid Leukemia1 trial

Skin Basal Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News